CanSino Biologics Inc
688185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,105
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,148.50 | 45.40 | 0.50% |
| CAC 40 | 7,880.87 | 10.19 | 0.13% |
| DAX 40 | 23,745.06 | 5.59 | 0.02% |
| Dow JONES (US) | 46,206.48 | 40.81 | -0.09% |
| FTSE 100 | 9,299.84 | 15.01 | 0.16% |
| HKSE | 26,622.88 | 494.68 | 1.89% |
| NASDAQ | 22,613.74 | 129.67 | 0.58% |
| Nikkei 225 | 45,043.75 | 311.24 | -0.69% |
| NZX 50 Index | 13,132.56 | 20.83 | 0.16% |
| S&P 500 | 6,659.85 | 16.15 | 0.24% |
| S&P/ASX 200 | 8,862.80 | 52.10 | 0.59% |
| SSE Composite Index | 3,862.53 | 34.43 | 0.90% |